Brief: Fibrobiologics Announces Release Of Cywc628 Drug Product For Phase 1/2 Diabetic Foot Ulcer Clinical Trial
04/05/2026 13:33
May 4 (Reuters) - Fibrobiologics Inc FBLG.O: FIBROBIOLOGICS ANNOUNCES RELEASE OF CYWC628 DRUG PRODUCT FOR PHASE 1/2 DIABETIC FOOT ULCER CLINICAL TRIAL FIBROBIOLOGICS INC - PHASE 1/2 TRIAL TO EVALUATE CYWC628 SAFETY, TOLERABILITY, AND EFFICACY IN DFU PATIENTS Source text: ID:nGNX9nmdqt Further company coverage: FBLG.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fibrobiologics
See all newsBrief: Fibrobiologics Files Patent Application For Technology Designed To Produce Glp-1 And Other Therapeutic Peptides Inside The Body
Brief: Fibrobiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair In Preclinical Study Of Degenerative Joints
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Brief: Fibrobiologics Granted US Patent Covering The Use Of Fibroblasts